Kestra Medical Technologies (NASDAQ:KMTS) Trading Up 10.2% – Still a Buy?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) were up 10.2% during mid-day trading on Thursday . The company traded as high as $22.82 and last traded at $22.7940. 4,992 shares changed hands during trading, a decline of 98% from the average session volume of 316,654 shares. The stock had previously closed at $20.69.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KMTS. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Finally, BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies has a consensus rating of “Hold” and an average price target of $27.40.

Kestra Medical Technologies Stock Performance

The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15. The stock’s 50 day moving average price is $20.86 and its two-hundred day moving average price is $22.76. The firm has a market capitalization of $1.27 billion, a PE ratio of -5.51 and a beta of 0.83.

Insider Activity

In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the sale, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 45,000 shares of company stock valued at $927,150 in the last quarter. 3.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC acquired a new stake in Kestra Medical Technologies in the 4th quarter worth about $31,000. Russell Investments Group Ltd. boosted its position in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after acquiring an additional 474 shares during the last quarter. BNP Paribas Financial Markets increased its position in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. acquired a new position in Kestra Medical Technologies during the fourth quarter worth approximately $72,000. Finally, Brown Brothers Harriman & Co. raised its stake in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares during the period.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.